Process for preparing hemifumarate of 5-{2-[benzyl-(1-(4-hydroxyphenyl)-1-methylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol
The described synthesis process efficiently produces fenoterol hydrobromide with a favorable RR,SS isomer ratio, addressing industrial yield issues and simplifying purification steps.
Patent Information
- Application Number
- FR2024004346
- Authority / Receiving Office
- FR · FR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-26
- Filing Date
- 2024-04-25
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2044-04-25
AI Technical Summary
Existing methods for synthesizing fenoterol hydrobromide result in an unacceptable ratio of RR,SS to RS,SR isomers, leading to low industrial yield and the need for lengthy purification processes.
A process involving the preparation of a solution with a protic acid, reduction of the carbonyl function, treatment with a base, and precipitation of a hemifumarate salt, followed by purification to achieve a desired isomer ratio.
The process achieves a high yield of the RR,SS isomer, meeting European Pharmacopoeia specifications without requiring extensive purification, such as column chromatography or repeated crystallizations.
Smart Images

Figure 00000033_0000 
Figure 00000034_0000
Abstract
Description
Title of the invention: Process for the preparation of 5-{2-[benzyl-(l-(4-hydroxyphenyl)-l-methylethyl)amino]-1-hydroxyethylbenzene-1,3-diol hemifumarate FIELD OF THE INVENTION
[0001] The present invention relates to the sector of processes for the synthesis of active ingredients for pharmaceutical use, and in particular to a process for the industrial-scale preparation of 5-{2-[benzyl-(1-(4-hydroxyphenyl)-1-methylethyl)amino]-1-hydroxyethyl]benzene-1,3-diol hemifumarate, a salt consisting of two molecules of 5-{2-[benzyl-(1-(4-hydroxyphenyl)-1-methylethyl)amino]-1-hydroxyethyl]benzene-1,3-diol and one molecule of fumaric acid, corresponding to the following formula:
[0002] 5-{2-[benzyl-(l-(4-hydroxyphenyl)-l-methylethyl)amino]-l-hy droxyethyl] benzene-1,3-diol hemifumarate is a useful intermediate in the synthesis of 5-[(lRS)-2-[(lRS)-2-(4-hydroxyphenyl)-l-methylethyl)amino]-l-hydroxyethyl]benzene-1,3-diol hydrobromide. STATE OF THE ART
[0003] The compound 5-[(lRS)-2-[(lRS)-2-(4-hydroxyphenyl)-l-methylethyl)amino]-l-hydroxyethyl]benzene-l,3-diol hydrobromide, also known by the common name fenoterol hydrobromide, has the structure shown below: QK
[0004] The compound is identified by CAS registry number 1944-12-3, as indicated in European Pharmacopoeia 10.0, page 2618, and belongs to the class of beta-adrenergic receptor agonists and sympathomimetic agents.
[0005]
[0006] Such derivatives can be used in the preparation of medicaments such as bronchodilator agents for the treatment of bronchospasm associated with asthma and bronchitis, and for the treatment of reversible airway obstruction. Fenoterol was first described in U.S. Patent No. 3,341,593, which described the class of compounds having the following general formula H
[0007] OH where R can be a hydrogen atom or a methyl group, and is a hydrogen atom in the specific case of fenoterol. The patent also discloses the possibility of using compounds having the formula indicated above in the form of their salts obtained by reaction with a pharmacologically acceptable acid, such as hydrobromic acid (HBr). Furthermore, the general description of US patent 3,341,593 reports, in a very general manner, the existence of mixtures of isomers due to the presence of one or two stereocenters (“asymmetric carbons”) indicated by the arrows in the figure OH
[0008]
[0009]
[0010] In the case of fenoterol, where R is a hydrogen atom, there are two stereocenters and four possible isomers, i.e., two diastereoisomers in the form of pairs of enantiomers (RR,SS; RS,SR). As indicated in the cited passage from the European Pharmacopoeia, the mixture of isomers used as the active ingredient is the one consisting of the pair of enantiomers RR,SS, because it has a favorable pharmacological activity. Still in the general part of document US 3,341,593, synthetic methods are described in a generic manner, but without going into detail on how to obtain the desired mixture of stereoisomers. The commercial availability of the racemic compound, structurally similar to fenoterol, formed by the following pair of enantiomers DH suggests to the skilled chemist, as a possible synthetic route, the reduction of the carbonyl function which, by exploiting the stereocenter already present in the molecule (indicated by the arrow) should lead to the obtaining of a favorable isomeric imbalance. The skilled person would therefore have reasonably assumed to obtain mainly the RR product from the R isomer, and mainly the SS isomer from the S isomer.
[0011] This approach was experimentally tested by the present applicant, with a laboratory-scale selection based on approximately 200 reduction experiments in which heterogeneous or homogeneous catalysts were used, with different chiral and non-chiral additives, solvents, temperatures, pressures and pH of the solutions. This experimental campaign led to excellent results regarding the carbonyl —> alcohol conversion yield (higher than 95%) but with a ratio of RR,SS to RS,SR isomers of 60 / 40 in the most favorable cases. The expected effect of the asymmetric induction due to the pre-existing stereocenter turned out to be much lower than expected, and the product of the synthesis has an unacceptable ratio between RR,SS and RS,SR isomers.
[0012] After synthesis, repeated crystallizations are necessary to obtain a final mixture in which the content of isomers having a favorable pharmacological activity respects the values provided for by the European Pharmacopoeia 10.0, leading to an overall yield so low that this solution is not industrially acceptable.
[0013] In light of the above, an efficient and industrially applicable method is therefore needed to maximize the formation of the RR,SS isomer mixture relative to the RS,SR mixture. SUMMARY OF THE INVENTION
[0014] This objective is achieved by the present invention, which relates to a process for the synthesis of 5-{2-[benzyl-(l-(4-hydroxyphenyl)-l-methylethyl)amino]-l-hydroxyethyl}benzene-l,3-diol hemifumarate, a compound which can be converted into fenoterol hydrobromide easily and with high yield. The method of the invention comprises the following steps: a) preparation of a solution comprising l-[3,5-dihydroxyphenyl]-2-[[2-(4-hydroxyphenyl)-l-methylethyl](phenylmethyl)amino]ethanone and a protic acid (HA) in a solvent chosen from: - water, - an alcohol chosen from methanol, ethanol and isopropanol, preferably methanol, - a mixture formed from water and an alcohol chosen from methanol, ethanol and isopropanol, preferably methanol, obtaining a salt, intermediate A, corresponding to the following formula: where A represents the deprotonated fraction of the protic acid HA; b) reduction of the carbonyl function of intermediate A obtaining intermediate B: ^terméiùaire 5 c) treatment of intermediate B with a base and a water-immiscible organic solvent, obtaining an organic solution of 5-{2-[benzyl-(l-(4-hydroxyphenyl)-l-methylethyl)amino]-l-hydroxyethyl}benzene-l,3-diol (intermediate C): GH f Intermediate C d) addition of fumaric acid to the organic solution obtained in step c), or vice versa, which leads to the precipitation of the hemifumarate salt, formed from two molecules of intermediate C and a molecule of fumaric acid, in crude form (intermediate D): Z) e) purification of crude intermediate D to give the desired product, 1 ' 5 - {2- [benzy 1- ( 1 - (4-hy droxyphény 1)-1 -méthyléthy 1) amino] -1 -hyd roxy éthyl] benzène-1,3-diol hemifumarate pure: BRIEF DESCRIPTION OF THE FIGURES
[0015] [Fig. 1] represents the X-ray diffractogram (XRPD) of the product of the invention. [Fig.2] represents the DSC thermogram carried out on the product of the invention. DETAILED DESCRIPTION OF THE INVENTION
[0016] The invention relates to a process for the synthesis of 5-{2-[benzyl-(l-(4-hydroxyphenyl)-l-methylethyl)amino]-l-hydroxyethyl]benzene-l,3-diol hemifumarate via steps a) to e) above.
[0017] Step a) consists of the preparation of a salt of l-[3,5-dihydroxyphenyl]-2-[[2-(4-hydroxyphenyl)-l-methylethyl](phenylmethyl)amino]ethanone with a protic acid (intermediate A): where A“ represents the deprotonated moiety, i.e. the conjugate base, of the protic acid HA.
[0018] Step a) can be carried out according to one of the alternative procedures a'), a”) and a'”): a') an aqueous solution of a protic acid and a solution formed by 1-[3,5-dihydroxyphenyl]-2-[[2-(4-hydroxyphenyl)-1-methylethyl](phenylmethyl)am ino]ethanone in a water-immiscible organic solvent are combined, obtaining a two-phase system; a") a mixture of a protic acid and the compound l-[3,5-dihydroxyphenyl]-2-[[2-(4-hydroxyphenyl)-l-methylethyl](phenylmethyl)amino]ethanone is prepared in an alcohol selected from methanol, ethanol and isopropanol, or in a mixture of water and one of these alcohols; the alcohol, whether used alone or mixed with water, is preferably methanol; a'") a two-phase system is prepared, comprising a water-immiscible organic solvent in which the compound l-[3,5-dihydroxyphenyl]-2-[[2-(4-hydroxyphenyl)-l-methylethyl](phenylmethyl)amino]ethanone is dissolved, and a phase consisting of water and an alcohol selected from methanol, ethanol and isopropanol in which a protic acid is present, and the water-immiscible organic solvent is evaporated.
[0019] The protic acid used in the salification operation of the starting compound can be organic or inorganic. - In the case of procedure a'), and in the case of the use of an organic protic acid, the acidic aqueous solution is obtained using one of the following acids: - L(+)tartaric acid (CAS 87-69-4); - D(-)tartaric acid (CAS 147-71-7); - DL-tartaric acid (CAS 133-37-9); - citric acid (CAS 77-92-9); - lactic acid (CAS 50-21-5); and - oxalic acid (CAS 144-62-7).
[0020] L(+)tartaric, D(-)tartaric and DL-tartaric acids are preferably used.
[0021] The aqueous solution is prepared at a concentration of 15 to 20% by weight of acid in water and has a pH < 6.
[0022] The organic solvent in which the compound l-[3,5-dihydroxyphenyl]-2-[[2-(4-hydroxyphenyl)-1-methylethyl](phenylmethyl)amino]ethanone is initially dissolved may be chosen from isopropyl acetate, methyl acetate, methyl isobutyl ketone and, preferably, ethyl acetate.
[0023] To the solution of l-[3,5-dihydroxyphenyl]-2-[[2-(4-hydroxyphenyl)-l-methylethyl] (phenylmethyl)amino]ethanone in an organic solvent, an amount of aqueous protic acid solution is added so that the pH of the resulting aqueous solution is less than 6, and preferably between 3 and 4. - In case a”), a solution of l-[3,5-dihydroxyphenyl]-2-[[2-(4-hydroxyphenyl)-l-methylethyl](phenylmethyl)amino]ethanone is prepared in a solvent consisting of an alcohol chosen from ethanol, isopropanol and, preferably, methanol, alone or mixed with water, and a protic acid chosen from: - fumaric acid (CAS 110-17-8); - succinic acid (CAS 110-15-6); - acetylsalicylic acid (CAS 50-78-2).
[0024] The preferred protic acid for performing procedure a”) is acetylsalicylic acid.
[0025] Both in the case of procedure a') and in the case of procedure a”), the reaction temperature is between 10 and 30 °C, preferably between 20 and 25 °C.
[0026] Finally, the inventors have found that by operating according to procedure a'), the extraction of intermediate A in aqueous phase does not occur with certain protic acids; these acids are maleic acid (CAS 110-16-7), acetic acid (CAS 64-19-7), hydrobromic acid (CAS 10035-10-6) and sodium hydrogen sulfate (CAS 7681-38-1). In this case, the procedure a'”) is operated, in which the organic solvent of the two-phase system is evaporated, and methanol is added, obtaining a hydroalcoholic solution containing intermediate A.
[0027] The preferred protic acid for carrying out procedure a'”) is maleic acid.
[0028] By operating according to any one of the procedures a'), a”) or a'”), we obtain a solution comprising intermediate A suitable for the next step of the process.
[0029] Step b) consists of the reduction of the carbonyl function of intermediate A to intermediate B:
[0030] If step a) has been carried out according to procedure a'), the solution containing intermediate A does not comprise alcohol, and the preliminary operation of step b) consists of the addition of an alcohol chosen from methanol, ethanol and isopropanol to said solution, operating at a temperature in the range from 0 to 30°C, preferably from 0 to 15°C; the preferred alcohol is methanol.
[0031] The hydroalcoholic solution containing intermediate A, resulting from step a) carried out according to method a”) or a'”), or from the prior operation indicated above, is used in the reduction reaction of the carbonyl function.
[0032] The reaction is carried out with a hydride chosen from sodium borohydride (NaBH4), lithium borohydride (LiBH4), calcium borohydride (Ca(BH4)2), zinc borohydride (Zn(BH4)2) and lithium cyanoborohydride (LiBH3CN); sodium borohydride is preferred.
[0033] The hydride is used in a molar ratio equal to or greater than 2 relative to the moles of intermediate A to be reduced. The reduction reaction may be completed by further additions of hydride and the protic acid used in step a); the addition of the acid as well as the further additions of hydride are necessary to maintain the pH of the solution in the acid range.
[0034] The reduction reaction is carried out at a temperature in the range of 0 to 35°C, preferably 0 to 25°C.
[0035] The result of the reaction is a hydroalcoholic solution containing intermediate B which is used as is in the next step.
[0036] Step c) consists of the treatment of intermediate B in a hydroalcoholic solution with a base and a water-immiscible organic solvent in order to obtain an organic solution of 5-{2-[benzyl-(l-(4-hydroxyphenyl)-l-methylethyl)amino]-l-hydroxyethyl]benzene-l,3-diol (intermediate C):
[0037] This step is carried out with a series of operations.
[0038] In the first operation, a base is added to the hydroalcoholic solution of step b), in an amount such that the pH of the solution varies from 6 to 8, and preferably from 6.5 to 7.5.
[0039] The base can be added in solid form (if the nature of the base allows it) or in the form of an aqueous solution. The bases useful for carrying out step c) are ammonia, NaOH, KOH, LiOH, Na2CO3, K2CO3, NaHCO3, KHCO3. Preferably, NaOH is used. To carry out step c), the temperature is maintained in the range from 0 to 25 °C, preferably from 0 to 5 °C.
[0040] The alcohol present in the hydroalcoholic solution is then evaporated by operating under reduced pressure, thus obtaining a suspension formed by intermediate C in water.
[0041] Alternatively, it is possible to reverse the sequence of base addition and alcohol evaporation, i.e. evaporate the alcohol first, thus obtaining an aqueous solution of intermediate B to which the base is added.
[0042] The mixture is then mixed with an organic solvent chosen from ethyl acetate (AcOEt), isopropyl acetate (AcOiPr) and methyl isobutyl ketone (MIBK), pure or mixed with methanol, stirring until dissolved; following this operation, a two-phase system is formed consisting of an aqueous phase and an organic phase.
[0043] The pH of the aqueous phase is then adjusted to a pH greater than or equal to 8, preferably in the range from 8.5 to 10, using a base. For this operation it is possible to use ammonia, NaOH, KOH, LiOH, Na2CO3, K2CO3, NaHCO3 and KHCO3; the preferred bases are NaOH and NaHCO3.
[0044] The phases are then separated, and the organic phase is concentrated under reduced pressure, obtaining an organic solution in which intermediate C is present.
[0045] Step d) consists of the precipitation of the hemifumarate salt (crude intermediate D) from the organic solution containing intermediate C in the presence of fumaric acid:
[0046] To carry out step d), an alcohol chosen from methanol, ethanol and, preferably, isopropanol, is added to the concentrated organic solution containing intermediate C obtained at the end of the previous step, and the resulting solution is added to fumaric acid, or vice versa, fumaric acid is added to said solution, at a temperature in the range from 20 to 65°C, preferably from 20 to 60°C.
[0047] The reaction mixture thus obtained is then stirred at a temperature in the range from 0 to 35°C, preferably from 15 to 30°C for at least 8 hours, preferably for 16 to 24 hours; following this operation, the precipitation of a solid is observed which is filtered to obtain the crude intermediate D.
[0048] Finally, step e) of the process of the invention consists of the purification of the crude intermediate D to give a product, defined below as pure hemifumarate, in which the ratio between the pairs of isomers RR,SS: RS,SR is that desired or higher: D Pure Hemifitmarate
[0049] To carry out step e), intermediate D (crude hemifumarate) is suspended in a linear or branched aliphatic C1 to C5 alcohol; preferably methanol is used. The suspension is stirred at reflux and then at 20-25°C. The product is recovered by filtration.
[0050] The purification procedure is repeated a number of times so as to obtain a content of undesirable isomers, RS,SR, of less than 5%; typically, 2 to 3 purifications are necessary to obtain this result.
[0051] The thus obtained 5-{(lRS)-2-[benzyl-((lRS)-(4-hydroxyphenyl)-l-methylethyl)amino]-l-hydroxyethyl]benzene-l,3-diol fumarate compound (2:1) has a lower content of undesirable isomers than the initial value present in intermediate D, and it can be used as an intermediate to obtain fenoterol hydrobromide conforming to the specifications of the European Pharmacopoeia 10.0, by subjecting it to chemical reactions known to the skilled chemist, some of which are illustrated in the experimental section; very briefly, the transformation of the pure hemifumarate reported above into fenoterol hydrobromide involves the initial formation of 5-{(lRS)-2-[benzyl-((lRS)-(4-hydroxyphenyl)-l-methylethyl)amino]-l-hydroxyethyl]benzene-l,3-diol hydrobromide via common acid-base reactions, the subsequent removal of the benzyl group attached to the nitrogen atom by catalytic hydrogenation, and finally the isolation of the desired product by simple crystallization from the solvent using a hot-cold technique.
[0052] Table 1 shows the results relating to the imbalance of the isomers obtainable using the process of the present invention (series 1 is for comparison purposes); the ratio of the isomers is calculated on the intermediate C obtained according to steps a), b) and c). [Tables 1] Series Procedure a' / a” / a”' Protic acid Ratio of desired / undesired isomers 1 / none 59 / 41 2 a' L-tartaric 78 / 22 3 a' D-tartaric 83 / 17 4 a' DL-tartaric 84 / 16 5 a” Fumaric 77 / 23 6 a'” Maleic 79 / 21 7 a' Citric 75 / 25 8 a” Succinic 78 / 22 9 a' Oxalic 80 / 20 10 a' Lactic 85 / 15 11 a'” Acetic 77 / 23 12 a” Acetylsalicylic acid 79 / 21 13 a'” Hydrobromic acid 78 / 22 14 a'” Sodium hydrogen sulfate 80 / 20
[0053] The invention therefore offers the advantage of providing a process for the synthesis of an intermediate of Fenoterol hydrobromide in which, during the synthesis process, the predominant formation of the stereoisomers is obtained which, transformed into Fenoterol, will give at the end of the process the racemate in accordance with the specifications of the European Pharmacopoeia 10.0, without the need for long and laborious purification processes, such as column chromatography or repeated crystallizations.
[0054] The invention will be further illustrated by the following examples. INSTRUMENTS, METHODS AND EXPERIMENTAL CONDITIONS
[0055] CLPH: description of the method for analyzing intermediates A, B, C, D
[0056] Instrument: Agilent Technologies 1100, 1200 or 1260 Infinity series; Column: Inertsil ODS-3; 150mm x 4.6mm x 3.0pm;
[0058] Flow rate: 0.8 ml / min;
[0059] Detector: 222 nm (DAD);
[0060] Bandwidth and reference for the DAD detector: 4 nm, 360 nm, 40 nm;
[0061] Temperature: 35°C;
[0062] Injection volume: 10 μL;
[0063] Pressure at t = 0': 123 bar. MOBILE PHASE Mobile phase “A CH3COONH4 0”77 g / L Mobile phase “B”: CH3CN GRADIENT OF THE METHOD [Tables 2] Time (min) Mobile phase “A” (%) Mobile phase “B” (%) 0 80 20 30 20 80 40 20 80 41 80 20 50 20 20
[0064] The samples were prepared for the series at a concentration of 0.25 g / L with a mobile phase “A” / mobile phase “B” 80 / 20 (v / v) mixture.
[0065] The samples were dissolved in the mobile phase “B” until an opalescent heterogeneous solution was obtained, then they were brought to volume by adding the mobile phase “A” and obtaining a homogeneous, colorless and clear solution.
[0066] The percentage of RR,SS and RS,SR isomers relative to intermediates C and D was determined from the value of the percentage area of the peaks as follows: - RR,SS isomers = % area of RR,SS / % area of RR,SS + % area of RS,SR); - RS,SR isomer = % area of RS,SR / (% area of RR,SS + % area of RS,SR).
[0067] NMR: Spectrometer: JEOL 400 YH NMR (400 MHz); Software: JEOL Delta v5.1.1; The spectra were recorded in deuterated solvents such as: Chloroform-d, D 99.8%, containing 0.1% (v / v) tetramethylsilane (TMS) as internal standard; and Chloroform-d, “100%”, D 99.96%, containing 0.03% (v / v) TMS, and DMSO-d6.
[0068] SM: Instrument: Agilent 1260 Infinity / 6120 Quadrupole LC / MS Software: OpenLAB 2 Ionization method: ESI - Electrospray ionization
[0069] SM parameters: Initial mass (m / z) 300 Da; Final mass (m / z) 500 Da; Scan time: 500 ms; Fragmentation: 70 V; Positive and negative polarity; Gas temperature: 350°C; Gas flow rate: 12 L / min; Nebulizer: 30 psi (2.07 bar); Positive capillary voltage 3000 V; Negative capillary voltage 3000 V; Flow rate: 0.3 ml / min; Injection: 1.0 pL; Mobile phase: H2O + 0.10% HCOOH / CH3CN + 0.10% HCOOH 50% / 50% (v / v).
[0070] CCM MERCK: CCM 60 silica gel F254 Aluminum sheets 20 x 20 cm, cod. 1.0554.0001.
[0071] Detectors for CCM Cerium phosphomolybdate: 25 g of phosphomolybdic acid and 10 g of cerium (IV) sulfate are dissolved in 600 ml of H2O. 60 ml of 98% H2SO4 are added and the resulting mixture is brought to 1 L with H2O. The plate is impregnated with the solution and then heated until the products are detected. Detector lamp: UV 254 nm and 366 nm.
[0072] XPRD XRPD analysis was performed using a Bruker® D2 Phaser diffractometer (2nd ed.). The X-ray source is an X-ray tube with a copper anode, operated at 30 kV and 10 mA. The analytical wavelength used is copper Ka (X = 1.54184 Å). K[3 was filtered through a nickel filter. The X-ray detector is a solid-state linear array detector model LYNXEYE. Samples were deposited in a thin layer on “zero-background” silicon sample holders. The diffractogram was recorded in the angular range of 4.0 to 40° 20 with 0.016° increments and a scan rate of 1.0 s / increment. The sample was rotated at 60 rpm during the analysis. Data were analyzed using DIFFRAC.EVA software (Bruker). All angular values given below should be understood within the usual approximation of ± 0.2°.
[0073] DSC DSC analysis was performed using a Mettler Toledo DSC3 instrument operating in a nitrogen atmosphere. Samples were prepared in 40 pL aluminum crucibles equipped with a lid and were crimped prior to analysis using the appropriate press, then the lid was pierced to allow possible free gas evolution of the sample. Analysis was performed at a constant heating rate of 10 °C / min. Data were analyzed using STARe software (Mettler Toledo). REMARKS
[0074] Water used in experimental descriptions should be understood as pure water, unless otherwise indicated.
[0075] The organic solvents used in the experimental descriptions are to be understood as being of “technical” quality, unless otherwise indicated.
[0076] The reagents and catalysts used in the experimental descriptions should be understood to be of commercial quality, unless otherwise indicated.
[0077] The term "small volume" reported in the following examples in reference to the volume of a solution after a distillation step, means 10% or less of the starting volume. - The following conventions and abbreviations are used in the following examples: - unless otherwise indicated, solution concentrations expressed as a percentage should be understood as weight concentrations; - MIBK: methyl isobutyl ketone; - DCM: dichloromethane; - MeOH: methanol; - IPA: isopropanol; - AcOEt: ethyl acetate; - Pd / C 5%: palladium supported on carbon, 5% by weight of Pd. EXAMPLE 1
[0078] This example refers to the preparation of compound 2, a precursor compound for use in a method of the invention.
[0079] 200 g of 4-methoxyphenylacetone in 1200 ml of toluene were charged into a flask. The system was brought to reflux and benzylamine (168 g) was added over one hour, maintaining the reflux temperature and removing the water formed. The line was rinsed with 15 ml of toluene. After the reaction was complete, 500 ml of toluene was distilled without vacuum, and then the system was converted to an oily residue by vacuum distillation at 95 °C. The residue was dissolved under nitrogen with MeOH (1386 ml) and the solution was cooled to 0 °C. Sodium borohydride (16 g) was added portion by portion and the mixture was stirred for 1 hour at 0-5 °C. After the reaction was complete, the mixture was distilled under vacuum to a residual volume of 500-600 ml. Water (400 ml) was charged and distillation was continued until the MeOH was completely removed. The residue was taken up with 1120 ml of water and 640 ml of DCM. The phases were separated and the aqueous phase was extracted again with DCM (100 ml).The organic phases were combined and washed with water (100 mL). The solvent of the organic phase was evaporated in vacuo. The residue was taken up with MeOH (400 mL) and water (266 mL). The system was cooled to <10 °C and a previously prepared solution of 37% HCl (133 g) and water (133 g) was added dropwise. The system was stirred at 0-5 °C for 30 min, and the solid was filtered and washed with water (270 mL). The solid was suspended in toluene (1067 mL) and the suspension was stirred at 25 °C for 30 min. The suspension was then filtered and washed with toluene (107 mL). Toluene . (667 ml) and water (400 ml) were added to the recovered solid. 30% sodium hydroxide (177 g) was added dropwise while maintaining the temperature < 30 °C. The phases were separated and the aqueous phase was extracted again with toluene (213 ml). The organic phases were combined and washed with water (270 g). The solvent was evaporated, recovering 226 g of compound 1.
[0080] Compound 1 (100 g; 0.392 mol) was added portionwise to a solution of 48% HBr in H2O (670 mL, 5.913 mol) at 50 °C. An additional 60 mL of a 48% H2O / HBr (5:1 v / v) solution was then added. The reaction mixture was heated to 110-120 °C and stirred for 4 hours. After monitoring by TLC, the reaction was found to be complete. The mixture was cooled to 0-5 °C and stirred for 1 hour. The precipitate was filtered (hydrobromide salt of compound 2) and washed with a 48% H2O / HBr (5:1 v / v) solution. The precipitate was suspended in 210 mL of H2O and 85 mL of MIBK, and then NH40H was added until pH > 10. The system was kept stirring at 0-5 °C for 1 h. The precipitate was filtered and washed with cold MIBK and H2O, and finally dried at 50 °C; product 2 (79.34 g) was recovered and used as such in a further reaction. EXAMPLE 2
[0081] This example refers to the preparation of compound 4, a precursor compound for use in a method of the invention. 1) 6¾ Ha / PAt DCM 2) NaHCDj 20%, 3) MëOH, H2O 3 4
[0082] Compound 3, diacetoxyacetophenone, is a commercially available product.
[0083] Compound 3 (100 g; 0.424 mol) was dissolved, under nitrogen flow, in DCM (500 ml). The system was cooled to 10-15 °C and a solution of HCl in PIPA (1.53 ml) was added thereto. The system was kept stirring for 5 minutes, cooled to 0-5 °C, and Br2 (23.87 ml; 0.466 mol) was deposited on it while maintaining T < 10 °C. The system was kept stirring at 0-5 °C for 30 minutes. A solution of NaHCO3 (9 g) in H2O (450 ml) was added dropwise to the system at 0-5 °C. The system was then heated to 20 °C and the phases were separated. The aqueous phase was extracted again with DCM (90 ml). The combined organic phases were washed with H2O and concentrated under vacuum at 35 °C to a small volume. MeOH (180 ml) and H2O (45 ml) were added to it. The system was kept stirring at 0-5 °C for 30 minutes. The precipitate was filtered and washed with MeOH / H2O (35:10 v / v) at 5 °C. 112.88 g of product 4 was recovered (after drying under reduced pressure). EXAMPLE 3
[0084] This example refers to the preparation of compound 5, a precursor compound for use in a method of the invention.
[0085] 50 g (0.159 mol) of compound 4 prepared as described in Example 2 were dissolved, under a nitrogen atmosphere, in 300 ml of nitrogen-degassed MIBK. 100 ml of solvent was evaporated in vacuo. 40 ml of nitrogen-degassed MIBK was added to the solution of compound 4, under nitrogen. The solution was heated to 50 °C and 76.58 g (0.317 mol) of compound 2 prepared as described in Example 1 was added thereto. The system was kept stirring for 1.5 h at 105 °C. TLC check: reaction complete. The system was brought to -10 °C and further stirred for 1 h. The precipitate was filtered and washed with nitrogen-degassed MIBK. The solvent was evaporated in vacuo at 50 °C and product 5 was recovered, which was used as such in the reaction of the following example. EXAMPLE 4
[0086] This example refers to the preparation of compound 6, a precursor compound for use in a method of the invention. 5
[0087] 115 ml of MeOH degassed with nitrogen, 2 ml of H2O and a 48 HBr solution % in H2O (27.01 ml; 0.238 mol) was added to compound 5 (0.159 mol), obtained as described in Example 3. The system was kept stirring at 70 °C for 30 minutes. TLC check: reaction complete. The system was cooled to 0-5 °C, and 22 ml of a 30% aqueous NaOH solution degassed with nitrogen was added, bringing the pH of the system to 7. The MeOH was evaporated in vacuo at 50 °C. Degassed H2O (105 ml) and AcOEt (250 ml) previously degassed were added, and the mixture was stirred at 50 °C until the product dissolved. 30% NaOH (6 ml) previously degassed with nitrogen was added until pH 8, and finally an aqueous NaHCO3 solution degassed with nitrogen (120 ml) was added until pH 8.5 / 9. The phases were separated. The aqueous phase was extracted again with AcOEt (280 mL) degassed with nitrogen. The combined organic phases, containing intermediate 6, were washed with H2O and used as such in the reaction of the following example. EXAMPLE 5
[0088] This example refers to step a') of the invention. g frîiWhéütetf® .A
[0089] A 20% aqueous solution of L(+)-tartaric acid (95.4 g; 0.636 mol in 380 ml of H2O) was prepared. 260 ml of the aqueous tartaric acid solution was added to the organic phase (solution containing intermediate 6, obtained as described in the previous example). The system was kept stirring for 10 minutes at 20 < T < 25 °C, and the phases were separated. The organic phase was extracted again with the remaining acid solution. The acidic aqueous phases were combined and washed with AcOEt (105 ml). Operating under vacuum at 55 °C, 70 ml of the acidic aqueous solution was evaporated; the remaining part containing the product (intermediate A) was used as such for the reaction of the following example.
[0090] For analytical purposes, an aliquot of the solution containing intermediate A was made basic with saturated aqueous NaHCO3 solution, extracted with AcOEt, and chromatographed on silica gel eluting with a toluene / AcOEt mixture in a gradient of 8 / 2 to 1 / 1.
[0091] The residue obtained (CLPH purity > 90%) was analyzed, providing the following data: 'H NMR (400 M Hz, DMSO-d6): ô 9.54 (s, 2H), 9.09 (s, 1H), 7.33-7.14 (m, 5H), 6.86 (d, J = 8.6 Hz 2H), 6.80 (d, J = 1.6 Hz, 2H), 6.61 (d, J = 8.6 Hz 2H), 6.44 (d, J = 1.6 Hz, 1H), 3.89 (s, 2H), 3.69 (ABq, J= 14.2 Hz, 2H), 2.88-2.80 (m, 2H), 2.38-2.33 (m, 1H), 0.90 (d, 7=6.4 Hz, 3H). 13C NMR (400 M Hz, DMSO-d6): δ 198.3, 158.3, 155.2, 140.0, 138.0, 130.2, 129.7, 128.3, 127.9, 126.6, 114.8, 106.9, 105.8, 56.8, 55.9, 54.2, 37.7, 14.8. EXAMPLE 6
[0092] This example refers to the method of the invention according to the sequence of steps: b); c); d) and WmàiWre 4 / / îte / ?néüfew® S ! here ) / 7 / 7 / / 7 / / 4^ / / ¾ »f / rf O
[0093] MeOH (485 ml) was added to the aqueous solution of intermediate A obtained as described in Example 5 at 0-5 °C.
[0094] 21.15 g of NaBH4 (0.557 mol) were added portion by portion to this new solution while maintaining T < 10 °C. The system was kept stirring for 30 minutes at 0-5 °C. With TLC monitoring, it was verified that the reaction was not complete. L(+)-Tartaric acid (47.7 g, 0.318 mol) and NaBH4 (14.5 g, 0.38 mol) were added portion by portion, and the system was kept under stirring for 1 h at 0-5 °C, checking the completion of the reaction by TLC. The result is a solution containing intermediate B.
[0095] 50 ml of a 30% NaOH solution was added to this solution, maintained at 0-5 °C, up to pH 7. The methanol was evaporated at 50 °C under vacuum. 430 ml of a mixture of AcOEt / MeOH (95:5 v / v) was added and the system was kept stirring at 50 °C until the product was completely dissolved. The solution was cooled to 20 °C and 75 ml of a 30% NaOH solution was added up to pH 8, and 200 ml of a saturated aqueous NaHCO3 solution was added up to pH 8.5 / 9. The phases were separated and the aqueous phase was extracted again with 330 ml of a mixture of AcOEt / MeOH (95:5 v / v). The organic phases were combined, the resulting phase was washed with H2O and concentrated in vacuo at 50 °C to a residual volume of 485 mL. The result of this operation is an organic solution containing intermediate C. 86 mL of IPA was added to the resulting solution, and the resulting solution was added to fumaric acid (23.99 g; 0.208 mol) at 50 °C.The system was kept stirring at 25 °C for 16 h. The formation of a precipitate was observed. The precipitate was filtered and washed with a mixture of AcOEt / IPA (95:5 v / v, 140 mL). The solid was dried at 48 °C, recovering 42.75 g of crude intermediate D.
[0096] A CLPH analysis was carried out on a sample of the solid thus obtained, which revealed a RR,SS vs RS,SR ratio of 82:18.
[0097] Crude intermediate D (20 g; 0.044 mol) was suspended in 200 mL of MeOH, and the system was stirred for 1 h at reflux, then cooled to 25 °C and stirred for 1 h. The precipitate was filtered, washed with 30 mL of a mixture of AcOEt / MeOH (95:5 v / v) and finally dried at 50 °C to obtain 14.77 g of crude intermediate D.
[0098] A CLPH analysis was carried out on a sample of the solid thus obtained, which revealed a RR,SS vs RS,SR ratio of 93:7.
[0099] The crude intermediate D thus obtained was suspended in 75 ml of MeOH, and the system was kept stirring for 1 h at reflux, then cooled to 25 °C and kept stirring for 1 h. The precipitate was filtered, washed with 20 ml of a mixture of AcOEt / MeOH (95:5 v / v), and finally dried at 50 °C, obtaining 13.4 of pure hemifumarate.
[0100] A CLPH analysis was carried out on a sample of the solid thus obtained, which revealed a RR,SS vs RS,SR ratio of 96:4.
[0101] The hemifumarate obtained at the end of the purification process was analyzed, providing the following results: H NMR (400 M Hz, DMSO-d6): 6.62 (s, 1H), 6.15 (d, J = 2 Hz, 2H), 6.05 (t, J = 2 Hz, 1H), 4.29 (t, J = 6.4 Hz, 1H), 3.70 (ABq, J = 13.8 Hz, 2H), 2.88-2.74 (m, 2H), 2.53-2.50 (m, *), 2.39-2.33 (m, 1H), 0.84 (d, J = 6.4 Hz, 3H). (*The integration of the signal at 2.53-2.50 is equal to 5 instead of 2, due to the presence of residual solvent peaks). 13C NMR (400 M Hz, DMSO-d6): δ 166.0, 157.9, 155.2, 146.3, 140.0, 134.0, 130.1, 129.7, 128.5, 127.9, 126.6, 114.8, 103.9, 100.9, 70.6, 57.7, 56.3, 54.2, 38.3, 13.6. Mass (CI): m / z = 394 [M++l]
[0102] An XRPD test provided the diffractogram shown in [Fig. 1]; the following table presents the list of peaks of the XPRD diffractogram: [Tables3] Angle 20 (°) Intensity % Angle 20 (°) Intensity % 6.83 100% 19.13 8% 8.21 4% 19.41 2% 9.46 4% 20.29 3% 9.88 68% 20.50 9% 11.41 19% 20.95 7% 11.76 2% 21.66 11% 12.57 5% 21.82 12% 13.32 3% 22.10 22% 13.64 13% 23.75 6% 13.99 2% 24.15 3% 16.01 11% 25.54 2% 16.43 14% 26.14 3 % 16.70 33% 26.84 5% 18.97 12% 27.71 3%
[0103] The most intense peaks are those at angles 6.83°, 9.88°, 11.41°, 16.43°, 16.70° and 22.10° ±0.2° 20.
[0104] 7.1 mg of the fenoterol hemifumarate sample was subjected to a DSC calorimetry; the test plot is shown in [Fig.2]; the most characteristic values detected in DSC calorimetry are an endotherm with a peak at 156 °C and an onset at 149 °C, and an endotherm with a peak at 175 °C and an onset at 167 °C. EXAMPLE 7
[0105] This example concerns the preparation of crude fenoterol hydrobromide from the hemifumarate obtained as described in Example 6.
[0106] 30 ml of H2O and 40 ml of a mixture of AcOEt / MeOH (95:5 v / v) were added to hemifumarate (4.08 g; 0.009 mol) followed by 1 mL of 30% NaOH to pH 7.5, and 20 mL of saturated aqueous NaHCO3 to pH 9. The system was stirred at 50 °C for 15 minutes, cooled to 25 °C, and the phases were separated. The aqueous phase was extracted again with 15 mL of AcOEt / MeOH (95:55 v / v). The combined organic phases were washed with H2O. The solvent from the organic phase was evaporated in vacuo at 50 °C, and the product with the formula below was recovered as the free base: OH
[0107] MeOH (22 mL), 48% HBr to pH 4-5, and 5% Pd / C (0.407 g) were added to this free base (3.55 g; 0.009 mol). The solution was hydrogenated with a gas bag for 3 hours at 40 °C. After monitoring by TLC, the reaction was found to be complete. The solution was filtered through dicalite and concentrated in vacuo at 50 °C to a small volume. AcOEt (18 mL) was added and the solution was concentrated in vacuo at 50 °C to a small volume. 35 mL of a mixture of AcOEt / MeOH (95:5 v / v) was added thereto. The system was kept stirring at 50 °C for 10 minutes and at 25 °C for 16 hours. A precipitate was obtained, which was filtered, washed with 5 mL of AcOEt / MeOH (95:5 v / v) mixture and dried at 50 °C to recover 2.84 g of crude fenoterol hydrobromide. EXAMPLE 8
[0108] This example refers to the purification of hydrobromide of Fenoterol obtained as in the previous example. whydf W tof de
[0109] 10.50 g of fenoterol hydrobromide, obtained according to the procedure of the example 7, were suspended in 95 ml of degassed water for injection (WFI). The system was heated to 50 °C until the solid was completely dissolved. The resulting aqueous solution was cooled to 25 °C and 1.05 g of carbon was added. The suspension was stirred for 30 minutes and then filtered through dicalite, washed with 10 ml of degassed WFI. The solution was concentrated in vacuo at 52 °C to a small volume. 35 ml of degassed AcOH was added. The system was concentrated in vacuo at 50 °C to a small volume. An additional 40 ml of degassed AcOH was added. The system was cooled to 25 °C and kept stirring for 1 h. A precipitate was obtained, which was filtered and washed with 10 ml of degassed AcOH and two 15 ml portions of degassed AcOEt, recovering 9.29 g (wet) of pure fenoterol hydrobromide.
[0110] 6.34 g of pure fenoterol hydrobromide was suspended in 70 ml of water degassed water for injection (WFI water). The system was heated to 55 °C until the solid was completely dissolved. The resulting solution was cooled to 35 °C and the pH was brought to 4 with the addition of 48% aqueous HBr solution diluted 1 in 10 with WFI water. The aqueous solution containing the product was filtered through a Millipore filter to remove any impurities, washed with degassed WFI water. The solution was concentrated in vacuo at 55 °C to a small volume. 5 ml of degassed EtOAc was added and filtered through a Millipore filter. The system was concentrated in vacuo at 55 °C to a small volume. An additional 9 ml of degassed EtOAc, filtered through a Millipore filter, was added and the system was concentrated in vacuo at 55 °C to a dense suspension.60 ml of AcOEt, degassed and filtered through a Millipore filter, was added and the system was refluxed with a jacket temperature of 100 °C for 3 h, periodically removing the water that condensed during reflux.
[0111] The system was cooled to 25 °C, kept at this temperature for 1 h, then filtered and washed with 5 ml of AcOEt. The product was dried under vacuum at 50 °C for 2 h, recovering 5.98 g of fenoterol hydrobromide conforming to the specifications of the European Pharmacopoeia 10.0. EXAMPLE 9
[0112] This example refers to the sequence of steps a”), b), c) and d) of the method of the invention. G g toîemîêdfM® A
[0113] 2.54 g of a solution containing intermediate 6 obtained as described in Example 4 (0.0065 mol) were evaporated under vacuum. The residue was dissolved in 35 ml of MeOH. Succinic acid (3.05 g, 0.0258 mol) and water (15 ml) were added to the solution, and the system was then kept stirring until the solid was completely dissolved.
[0114] NaBH4 (0.865 g; 0.023 mol) was added portion by portion to the solution while maintaining T < 10 °C. The system was kept stirring for 1 hour at 25 °C. Upon TLC monitoring, it was verified that the reaction was not complete. Succinic acid (3.05 g) and, portion by portion, NaBH4 (0.865 g) were added and the system was kept stirring for 30 minutes at 25 °C. Upon TLC monitoring, the reaction was complete. Operating at 0-5 °C, 30% NaOH was added until pH 7. Methanol was evaporated at 50 °C under vacuum. 20 ml of AcOEt / MeOH (95:5 v / v) mixture was added and the system was kept stirring at 50 °C until the product was completely dissolved. The solution was cooled to 20 °C and 30% NaOH was added until pH 8; then, the pH was brought to 8.5-9 with aqueous NaHCO3 solution. The phases were separated.The aqueous phase was extracted again with a mixture of AcOEt / MeOH (95:5 v / v, 10 mL). The combined organic phases were washed with H2O. The organic phase was concentrated in vacuo at 50 °C by evaporating about 12 mL of solvent, obtaining a solution containing intermediate C. 5 mL of IPA was added to the solution, and the resulting solution was added to fumaric acid (0.981 g). while maintaining the system temperature at 50 °C. The system was kept stirring at 50 °C for 20 min, then at 25 °C for 16 h. The precipitate was filtered, washed with a mixture of AcOEt / IPA (95:5 v / v, 5 ml) and dried at 50 °C, obtaining 1.55 g of crude intermediate D.
[0115] A CLPH analysis was carried out on a sample of the solid thus obtained, which revealed a RR,SS vs RS,SR ratio of 81.5:18.5. EXAMPLE 10 This example refers to the sequence of steps a'”), b), c) and d) of the method of the invention 0 6
[0116] An aqueous solution of maleic acid (11.14 g of maleic acid in 44.5 ml of water) was prepared. A solution of intermediate 6 in AcOEt (65 ml of solution corresponding to 0.012 mol of intermediate) obtained as described in Example 4 was washed with the aqueous solution of maleic acid (the product was in the organic phase).
[0117] The organic solvent was evaporated from the two-phase system using a rotary evaporator. MeOH (35 ml) was added with stirring until the solid present was completely dissolved.
[0118] The system was brought to a temperature of 0 to 5 °C, and NaBH4 (1.6 g; 0.042 mol) was added portion by portion while maintaining T < 10 °C. The system was kept stirring for 30 minutes at 5 °C. TLC check: incomplete reaction. NaBH4 (1.4 g; 0.037 mol) was added portion by portion while maintaining T < 10 °C. The system was kept stirring for 30 minutes at 5 °C. TLC check: incomplete reaction. Maleic acid (5.78 g) dissolved in water (25 ml) and MeOH (25 ml) were added. NaBH4 (1.91 g, 0.05 mol) was added portion by portion and the system was kept stirring for 30 minutes at 5 °C. Water (10 ml) and MeOH (10 ml) were added to dissolve the precipitate formed. TLC check: incomplete reaction. MeOH (25 ml) was added. Maleic acid (6.29 g) dissolved in water (30 ml) was was then added. NaBH4 (1.29 g, 0.034 mol) was added portion by portion and the system was kept stirring for 15 minutes at 5 °C. TLC check: reaction complete. 30% NaOH was added at 0-5 °C until about pH 8. Methanol was evaporated at 50 °C in vacuo. 40 ml of a mixture of AcOEt / MeOH = 95 / 5 v / v was added and the system was kept stirring at 50 °C until the product was completely dissolved. 50 ml of an aqueous solution of NaHCO3 was added, bringing the pH to about 8.5. The phases were separated and the aqueous phase was extracted again twice with 20 ml of a mixture of AcOEt / MeOH = 95 / 5 v / v. The combined organic phases were washed with H2O (20 mL) twice. The organic phase was concentrated in vacuo at 50 °C by evaporating approximately 20 mL of solvent to obtain a solution containing intermediate C.IPA (7 mL) was added to the solution, and the resulting solution was added to fumaric acid (1.8 g) while maintaining the temperature at 50 °C. The system was kept stirring at 50 °C for 1 h, then at 20 °C for 16 h. The precipitate was filtered, washed with AcOEt (5 mL), and dried at 50 °C, obtaining 0.87 g of crude intermediate D.
[0119] A CLPH analysis was carried out on a sample of the solid thus obtained, which revealed a RR,SS vs RS,SR ratio of 86:14. EXAMPLE 11
[0120] This example refers to the sequence of steps a”), b) and c) of the method of the invention.
[0121] An acidic aqueous solution (2.7 g of 48% HBr and 4 ml of water) was added to a solution of intermediate 6 (0.004 mol) in AcOEt prepared as described in Example 4.
[0122] The two-phase mixture was concentrated under reduced pressure in a rotavapor at 50 °C until the organic solvent was removed. MeOH (15 mL) was added and the temperature was increased to 0-5 °C. NaBH4 (0.456 g; 0.012 mol) was added portion by portion and the system was stirred for 20 min at 5 °C. TLC check: incomplete reaction. 48% HBr (1.81 mL) was added, then NaBH4 (0.456 g; 0.04 mol) was added portion by portion. The system was stirred at 5 °C for 20 min. The system was cooled to 0-5 °C and 30% NaOH was added until about pH 7. Methanol was evaporated at 50 °C in vacuo. 20 ml of a mixture of AcOEt / MeOH = 95 / 5 and 10 ml of water were added. The pH was brought to 8.8 with aqueous NaHCO3 solution (ss). The phases were separated and the aqueous phase was extracted again with a mixture of AcOEt / MeOH = 95 / 5 (30 ml). The combined organic phases were washed with H2O. The organic phase was was concentrated in vacuo at 50 °C to obtain intermediate C as an oil (2.19 g).
[0123] A CLPH control revealed a RR,SS vs RS,SR ratio of 78:22. EXAMPLE 12
[0124] This example refers to the sequence of steps a'”), b) and c) of the method of the invention.
[0125] A solution of NaHSO4 (1.92 g) in 11 ml of water was prepared, which was added to a solution of intermediate 6 (0.004 mol) in AcOEt prepared as described in Example 4. The two-phase mixture was concentrated under reduced pressure at T = 50 °C until the organic solvent was removed. 13 ml of MeOH was added and the system was stirred until complete dissolution. NaBH4 (0.456 g; 0.012 mol) was added portion by portion, the temperature was lowered to 5 °C and the system was stirred for 20 minutes at this temperature. TLC check: incomplete reaction. NaHSO4 (3.84 g), then, portion by portion, NaBH4 (0.912 g; 0.08 mol) were added at 5 °C. The system was stirred at 25 °C for 10 minutes, cooled to 0-5 °C, and 30% aqueous NaOH solution was added to approximately pH 7. Methanol was evaporated at 50 °C under vacuum. 11 ml of a mixture of AcOEt / MeOH = 95 / 5 was added.The system was brought to about pH 8.5 with aqueous NaOH solution. The phases were separated and the aqueous phase was extracted again with 20 mL of a mixture of AcOEt / MeOH = 95 / 5. The combined organic phases were washed with H2O. The organic phase was concentrated in vacuo at 50 °C to obtain intermediate C as an oil (1.92 g).
[0126] By CLPH control, a RR,SS vs RS,SR ratio of 80:20 was detected.
Claims
1. Claims A process for the synthesis of 5-{2-[benzyl-(l-(4-hydroxyphenyl)-l-methylethyl)amino]-l-hydroxyethyl}benzene-l,3-diol hemifumarate, comprising the following steps: a) preparation of a solution comprising l-[3,5-dihydroxyphenyl]-2-[[2-(4-hydroxyphenyl)-1-methylethyl](phenylmethyl)amino]ethanone and a protic acid (HA) in a solvent chosen from: - water, - an alcohol chosen from methanol, ethanol and isopropanol, - a mixture formed from water and an alcohol chosen from methanol, ethanol and isopropanol obtaining a salt, intermediate A, corresponding to the following formula: where A“ represents the deprotonated moiety of the protic acid HA; b) reduction of the carbonyl function of intermediate A to obtain intermediate B: TOH c) treatment of intermediate B with a base and a water-immiscible organic solvent, obtaining an organic solution of 5-{2-[benzyl-(1-(4-hydroxyphenyl)-1-methylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol (intermediate C): d) addition of fumaric acid to the organic solution obtained in step c), or vice versa, which leads to the precipitation of the hemifumarate salt, formed from two molecules of intermediate C and one molecule of fumaric acid, in crude form (intermediate D): e) purification of crude intermediate D to give the desired product, pure 5-{2-[benzyl-(l-(4-hydroxyphenyl)-l-methylethyl)amino]-l-hydroxyethyl}benzene-l,3-diol hemifumarate:
2. A method according to claim 1, wherein step a) is carried out according to a first method a'), combining an aqueous solution of a protic acid and a solution formed by 1-[3,5-dihydroxyphenyl 1]-2-[[2-(4-hydroxyphenyl)-1-methylethyl 1] (phenylmethyl)amino]ethanone in a water-immiscible organic solvent, obtaining a two-phase system.
3. A method according to claim 2, wherein said aqueous solution of a protic acid is prepared at a concentration of 15 to 20% by weight in water of a protic acid selected from L(+)tartaric acid, D(-)tartaric acid, DL-tartaric acid, citric acid, lactic acid and oxalic acid, and has a pH < 6.
4. A method according to any one of claims 2 or 3, wherein said water-immiscible organic solvent is selected from ethyl acetate, isopropyl acetate, methyl acetate and methyl isobutyl ketone.
5. A method according to claim 1, wherein step a) is carried out according to a second method a”), preparing a mixture of a protic acid and the compound l-[3,5-dihydroxyphenyl]-2-[[2-(4-hydroxyphenyl)-l-methylethyl](phenylmethyl)amino]ethanone, wherein the protic acid is selected from fumaric acid, succinic acid and acetylsalicylic acid, in an alcohol selected from methanol, ethanol and isopropanol, alone or in a mixture with water.
6. A process according to any one of claims 2 to 5, wherein the reaction temperature of step a') or step a”) is in the range of 10 to 30°C.
7. A method according to claim 1, wherein step a) is carried out according to a third method a'”), preparing a two-phase system comprising a water-immiscible organic solvent in which the compound l-[3,5-dihydroxyphenyl]-2-[[2-(4-hydroxyphenyl)-l-methylethyl](phenylmethyl)amino]ethanone is dissolved, and a phase consisting of water and an alcohol selected from methanol, ethanol and isopropanol in which a protic acid selected from maleic acid, acetic acid, hydrobromic acid and sodium hydrogen sulfate is present, and evaporating the water-immiscible organic solvent.
8. A method according to any one of claims 2 to 4 wherein, before carrying out step b), an alcohol selected from methanol, ethanol and isopropanol is added to said two-phase system, operating at a temperature in the range of 0 to 30°C.
9. A process according to any preceding claim, wherein the reduction reaction of step b) is carried out with a hydride selected from sodium borohydride, lithium borohydride, calcium borohydride, zinc borohydride and lithium cyanoborohydride, used in a molar ratio greater than or equal to 2 relative to the moles of intermediate A to be reduced, at a temperature in the range from 0 to 35°C.
10. A method according to any one of the preceding claims, wherein the reaction of step c) is carried out with the following series of operations: - adding a base to the hydroalcoholic solution of step b) in an amount such that the pH of the solution is in the range from 6 to 8, maintaining the temperature in the range between 0 and 25 °C; - before or after said addition of a base, evaporating the alcohol present in said hydroalcoholic solution by operating at reduced pressure, obtaining a suspension formed by intermediate C in water; - adding to said suspension an organic solvent chosen from ethyl acetate, isopropyl acetate and methyl isobutyl ketone, pure or mixed with methanol, stirring until dissolved, obtaining a two-phase system consisting of an aqueous phase and an organic phase;- regulating the pH of the aqueous phase to a value greater than or equal to 8, preferably in the range from 8.5 to 10, using a base chosen from ammonia, NaOH, KOH, LiOH, Na2CO3, K2CO3, NaHCO3 and KHCO3; - separating the phases and concentrating the organic phase under reduced pressure, obtaining an organic solution in which intermediate C is present.;
11. A process according to any one of the preceding claims wherein, before step d), an alcohol selected from methanol, ethanol and isopropanol is added to the organic solution obtained at the end of step c), and the resulting solution is added to fumaric acid, or vice versa fumaric acid is added to said solution, at a temperature in the range of 20 to 65°C, and the mixture thus obtained is stirred at a temperature in the range of 0 to 35°C for at least 8 hours, resulting in the precipitation of a solid which is filtered to obtain the crude intermediate D.
12. A process according to any one of the preceding claims, wherein in step e) intermediate D is suspended in a linear or branched C1 to C5 aliphatic alcohol, the resulting suspension is stirred first at reflux and then at 20-25°C, and finally the product is recovered by filtration, and said step e) is repeated two or three times.
13. A method according to any one of the preceding claims, further comprising a further step of converting 5-{(lRS)-2-[benzyl-((lRS)-(4-hydroxyphenyl)-l-methylethyl)amino]-l-hydroxyethyl]benzene-1,3-diol hemifumarate into fenoterol hydrobromide by the following steps: - forming 5-{(lRS)-2-[benzyl-((lRS)-(4-hydroxyphenyl)-l-methylethyl)amino]-l-hydroxyethyl]benzene-1,3-diol hydrobromide by reacting the hemifumarate with a base; - removal of the benzyl group linked to the nitrogen atom of 5-{(lRS)-2-[benzyl-((lRS)-(4-hydroxyphenyl)-l-methylethyl)amino]-l-hydroxyethyl]benzene-1,3-diol by catalytic hydrogenation; - isolation of the desired product by crystallization from the solvent with the hot-cold technique.
Citation Information
Patent Citations
1-p-hydroxyphenyl-2-(beta-3', 5'-dihydroxyphenyl-beta-hydroxy)-ethylamino-propanes
US3341593A
